Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys

Vanessa Minervini, Alex Disney, Stephen M. Husbands, Charles P. France

Research output: Contribution to journalArticlepeer-review

7 Citations (SciVal)

Abstract

Rationale: Opioid abuse remains a serious public health problem. The pseudoirreversible mu opioid receptor antagonist methocinnamox (MCAM) might be useful for treating opioid abuse and overdose. Because endogenous opioid systems can modulate cognition and decision-making, it is important to evaluate whether long-term blockade of mu opioid receptors by MCAM adversely impacts complex operant behavior involving memory. Objective: This study tested the effects of MCAM in rhesus monkeys responding under a delayed matching-to-sample task, with correct responses reinforced by sucrose pellets. Because MCAM did not alter performance, antagonism of the rate-decreasing effects of morphine was used to confirm that an effective dose of MCAM was administered. Moreover, the muscarinic receptor antagonist scopolamine and the N-methyl-D-aspartate antagonist phencyclidine were studied as positive controls to demonstrate sensitivity of this procedure to memory disruption. Results: Neither MCAM (0.32 mg/kg) nor morphine (1–5.6 mg/kg) impaired delayed matching-to-sample accuracy. Morphine dose-dependently decreased the number of trials completed before MCAM administration, and a single injection of MCAM blocked the behavioral suppressant effects of morphine for at least 7 days. Scopolamine (0.01–0.056 mg/kg) and phencyclidine (0.1–0.56 mg/kg) dose-dependently decreased delayed matching-to-sample accuracy and the number of trials completed. Conclusions: MCAM did not impair memory (as measured by accuracy in a delayed matching-to-sample task) and did not decrease responding for or consumption of sucrose pellets. This dose of MCAM attenuates self-administration of opioids and reverses as well as prevents opioid-induced respiratory depression. These results provide further support for a favorable adverse effect profile for MCAM.

Original languageEnglish
Pages (from-to)3057–3065
JournalPsychopharmacology
Volume237
Early online date9 Aug 2020
DOIs
Publication statusPublished - 31 Oct 2020

Funding

This work was supported by the National Institutes of Health (NIH) National Institute on Drug Abuse (Grants R01DA005018 (to CPF), R01DA048417 (to CPF), and R01DA07315 (to SMH)) and the Welch Foundation (Grant AQ-0039 (to CPF)). The content expressed here is solely the responsibly of the authors and does not necessarily represent the views of the NIH.

Keywords

  • Antagonism
  • Cognition
  • Memory
  • Operant behavior
  • Opioid
  • Rhesus monkey

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys'. Together they form a unique fingerprint.

Cite this